Aussie cost watchdogs slam cancer pricing in leaked report; Novartis lays off 89 at NY plant;

@FiercePharma: Sanofi's Shantha ready to supply 37 million doses of long-delayed pentavalent. FierceVaccines story | Follow @FiercePharma

@EricPFierce: When it comes to Big Pharma revenues, who's the biggest of them all? Special report | Follow @EricPFierce

@CarlyHFierce: Don't forget that there are FOUR regions to vote in today - let's show the oncology drugs some love, shall we? More on FierceMadness | Follow @CarlyHFierce

> In a leaked report to Australia's Senate, cost-effectiveness watchdogs slammed big drugmakers for high cancer drug prices, particularly those with smaller survival benefits. Report

> As part of an ongoing cost-cutting drive, Novartis ($NVS) is laying off 89 workers in Suffern, NY, where a plant is slated for closure. Report

> Investment in the Indonesian drug industry isn't growing much, despite a government program for universal insurance coverage. Report

> Antipsychotic drugs may be more dangerous to elderly patients than previously thought, according to a new study. Report

Medical Device News

@FierceMedDev: ICYMI: Vivo Capital doubles down to close $750M US-China healthcare fund. Story | Follow @FierceMedDev

@VarunSaxena2: Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Story | Follow @VarunSaxena2

@EmilyWFierce: Changes in public's perceptions of risk contributes to spread of infectious diseases, says NIAID director. More from The Atlantic | Follow @EmilyWFierce

> Boston Scientific subsidiary hit with $50M gender discrimination suit. Report

> Canon BioMedical makes first move with rapid DNA, drug metabolism diagnostic startup. Story

> Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Article

Biotech News

@FierceBiotech: J&J stays mum about cash, but biotech buyout is a landmark win for Index fund. Story | Follow @FierceBiotech

@JohnCFierce: Crohn's expert flags blockbuster potential--and frets--of Celgene's mongersen. News | Follow @JohnCFierce

@DamianFierce: Today begins the round of 64 in FierceMadness, a pointless & absurd tournament of drug names. More | Follow @DamianFierce

> Lilly inks a $690M deal to get its hands on an autoimmune drug. Article

> Genmab buys iDD antibody assets, drops ADC co-development rights. Story

> Google's mystery biotech Calico partners with the Broad on aging-related drugs. News

CRO News

> Quintiles taps Google partner Tute Genomics for R&D. Item

> Trial tech outfit Clinical Ink merges with app upstart. News

> Evotec pairs up with Second Genome to gut out some R&D. More

> Catalent shakes up its business with an eye on product launches. Story

> WuXi dives into the CAR-T fray with new plant plans. Article

Vaccines News

> Cancer vaccine maker Aduro files for $86M IPO. Item

> Allergy Therapeutics scores $30M to finish grass allergy vaccine. More

> England to provide GSK MenW vaccine to 3 million teens. News

> GSK to test Ebola jab with booster from Emergent BioSolutions. Report

> More vaccines deals for Pfizer? It wouldn't say no, exec says. Story

Pharma Manufacturing News

> Puerto Rico manufacturing base to grow with AbbVie expansion. More

> Kite Pharma adds manufacturing assets with T-Cell Factory acquisition. Item

> India's Micro Labs recalls drugs made at banned plant. Report

> Wockhardt says FDA impressed by the strides it made at a banned plant. Article

> Lawsuit would force FDA to ban or label wheat gluten as ingredient. Story

Pharma Asia News

> U.S.-based lawsuits pile up for Japan's Olympus in superbug case. Item

> Indonesia drug industry investment lags despite universal insurance program. Article

> Daiichi Sankyo pays $200M to AstraZeneca for Movantik U.S. sales rights. Story

> U.S. FDA softens approach in meetings with Indian regulators. Report

> India's Wockhardt, Granules, suggest recent FDA inspections went well. More

And Finally... Coke ($KO) and Pepsi ($PEP) are searching for a new generation of sweeteners for diet soda. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.